about
sameAs
Rapid improvement in verbal fluency and aphasia following perispinal etanercept in Alzheimer's disease.Alzheimer's Disease: Exploring the Role of Inflammation and Implications for TreatmentEmerging technologies for molecular therapy for intervertebral disk degenerationExcess cerebral TNF causing glutamate excitotoxicity rationalizes treatment of neurodegenerative diseases and neurogenic pain by anti-TNF agentsNanoparticle fullerol alleviates radiculopathy via NLRP3 inflammasome and neuropeptides.Novel treatment of neuroinflammation against low back pain by soluble fullerol nanoparticlesPerispinal etanercept for post-stroke neurological and cognitive dysfunction: scientific rationale and current evidenceDistribution and tumor necrosis factor-alpha isoform binding specificity of locally administered etanercept into injured and uninjured rat sciatic nerve.Immediate anti-tumor necrosis factor-alpha (etanercept) therapy enhances axonal regeneration after sciatic nerve crush.Genome-wide analysis of pain-, nerve- and neurotrophin -related gene expression in the degenerating human annulusCatabolic cytokine expression in degenerate and herniated human intervertebral discs: IL-1beta and TNFalpha expression profile.Perispinal Delivery of CNS Drugs.An injectable and in situ-gelling biopolymer for sustained drug release following perineural administration.Spinal delivery of p38: TNF-alpha inhibitors.Authors' reply to Whitlock: Perispinal etanercept for post-stroke neurological and cognitive dysfunction: scientific rationale and current evidence.Use of Temporary Implantable Biomaterials to Reduce Leg Pain and Back Pain in Patients with Sciatica and Lumbar Disc Herniation.
P2860
Q21261380-428ACF58-75AB-4EA6-8A39-16382487318FQ26776157-B0C7DD5D-05A1-4090-AA0C-E31D15B05AB4Q27693848-82BFE2B0-63F0-46BB-A649-C67C6FC63FE3Q28075692-0B5BBB29-2665-45AD-9843-A84479B31834Q30252648-EA514C78-F9BD-45AD-A4A8-85CCF93488AAQ30417501-486EC1B6-3AB3-4947-A774-A882DF85BE7BQ33947639-55E0E3FB-5E26-42C4-983E-5D17B5A9CED8Q35776382-497121B1-CC92-424B-85A1-46669251E333Q35776433-1EE216F2-C0A4-44F0-A7C6-46677F541B1CQ36391737-5EB3BE1F-74DF-42EF-B7BF-F2284DC4DC09Q36392389-82E034EF-489A-4E9E-AF17-136F5268B8D2Q38819013-420B75F3-0341-497B-9CF4-200504BDE613Q41791113-EEDB4F22-26EC-43DA-80B8-00DFBCE940D2Q42725130-F24F6446-0F21-40B0-902C-DA115FF582D1Q43041358-854C28FD-3CB4-4AB5-8521-E5400CEC3373Q50281388-D1C0A274-0510-4F45-80C8-A93A332ED687
P2860
description
2003 nî lūn-bûn
@nan
2003 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի մարտին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Perispinal TNF-alpha inhibition for discogenic pain
@ast
Perispinal TNF-alpha inhibition for discogenic pain
@en
Perispinal TNF-alpha inhibition for discogenic pain
@nl
type
label
Perispinal TNF-alpha inhibition for discogenic pain
@ast
Perispinal TNF-alpha inhibition for discogenic pain
@en
Perispinal TNF-alpha inhibition for discogenic pain
@nl
prefLabel
Perispinal TNF-alpha inhibition for discogenic pain
@ast
Perispinal TNF-alpha inhibition for discogenic pain
@en
Perispinal TNF-alpha inhibition for discogenic pain
@nl
P3181
P1433
P1476
Perispinal TNF-alpha inhibition for discogenic pain
@en
P2093
Edward L Tobinick
Susan Britschgi-Davoodifar
P3181
P407
P577
2003-03-22T00:00:00Z